BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 15150682)

  • 1. Transplacental passage of Pt after treatment with the new triamine complex cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate.
    Ognio E; Chiavarina B; Caviglioli G; Lapide M; Viale M
    Arch Toxicol; 2004 Oct; 78(10):584-8. PubMed ID: 15150682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Embryo-lethal and teratogenic effect of the new platinum compound DPR in pregnant mice.
    Ognio E; Lapide M; Ottone M; Mandys V; Peterka M; Parodi B; Viale M
    Arch Toxicol; 2003 Oct; 77(10):584-90. PubMed ID: 14574446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Embryotoxicity of cisplatin and a cisplatin-procaine complex (DPR) studied in chick embryo.
    Peterka M; Mandys V; Viale M; Cafaggi S; Peterková R; Esposito M
    Neoplasma; 2002; 49(6):394-400. PubMed ID: 12584587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and antitumor activity of a new cis-diammineplatinum (II) complex containing procaine hydrochloride.
    Cafaggi S; Esposito M; Parodi B; Vannozzi MO; Viale M; Pellecchia C; Fulco RA; Merlo F; Zicca A; Cadoni A
    Anticancer Res; 1992; 12(6B):2285-92. PubMed ID: 1295476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity and cellular accumulation of a new cis-diammineplatinum (II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II).
    Viale M; Cafaggi S; Parodi B; Esposito M
    Cancer Chemother Pharmacol; 1995; 35(5):371-6. PubMed ID: 7850917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cell growth, induction of apoptosis and mechanism of action of the novel platinum compound cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N(4)]-chloride platinum (II) monohydrochloride monohydrate.
    Mariggiò MA; Cafaggi S; Ottone M; Parodi B; Vannozzi MO; Mandys V; Viale M
    Invest New Drugs; 2004 Jan; 22(1):3-16. PubMed ID: 14707490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
    Kim WK; Kwon YE
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
    Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the toxicities of cisplatin and a new cisplatin-procaine complex to rat renal cortical slices.
    Zhang JG; Esposito M; Cafaggi S; Lindup WE
    Hum Exp Toxicol; 1996 Jan; 15(1):59-63. PubMed ID: 8845212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
    Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
    Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotoxic effect of cisplatin and the cisplatin-procaine complex DPR studied in organotypic cultures of chick embryonic dorsal root ganglia.
    Mandys V; Viale M; Vrana J; Cafaggi S; Esposito M
    Anticancer Drugs; 1998 Aug; 9(7):659-63. PubMed ID: 9773811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum.
    Cerri S; Piccolini VM; Santin G; Bottone MG; De Pascali SA; Migoni D; Iadarola P; Fanizzi FP; Bernocchi G
    Neurotoxicol Teratol; 2011; 33(2):273-81. PubMed ID: 20883777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
    Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH
    Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
    Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
    Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
    Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
    Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
    Viale M; Vannozzi MO; Pastrone I; Mariggiò MA; Zicca A; Cadoni A; Cafaggi S; Tolino G; Lunardi G; Civalleri D; Lindup WE; Esposito M
    J Pharmacol Exp Ther; 2000 Jun; 293(3):829-36. PubMed ID: 10869382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum levels in murine tumor following intraperitoneal administration of cisplatin or paraplatin.
    Douple EB; Totten MD; Spencer F
    NCI Monogr; 1988; (6):129-32. PubMed ID: 3281028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
    Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.